Clinical trials: Ticagrelor
Peripheral Arterial Disease
Establishing the Microcirculatory Effects of Ticagrelor on Tissue Perfusion in Critical Limb Ischemia
This is a single center, prospective, randomized, unblinded, open-label, active controlled pilot study to evaluate the efficacy and safety of ticagrelor plus aspirin versus clopidogrel plus aspirin in patients with Rutherford…
- Trial name
- NCT02230527
- Testing
- Ticagrelor, Clopidogrel
- Where
- United States
- Volunteers
- 46 people
- Sponsor
- The Cleveland Clinic
Atrial Fibrillation, Percutaneous Coronary Intervention
Evaluation of Dual Therapy With Dabigatran vs. Triple Therapy With Warfarin in Patients With AF That Undergo a PCI With Stenting (REDUAL-PCI)
The main objective of this study is to compare a Dual Antithrombotic Therapy (DAT) regimen of 110mg dabigatran etexilate b.i.d. plus clopidogrel or ticagrelor (110mg dabigatran etexilate (DE) DAT) and 150mg dabigatran etexilate…
- Trial name
- NCT02164864
- Testing
- Dabigatran Etexilate 110mg, Warfarin 3mg, Aspirin
- Where
- 421 sites in United States, Argentina and 39 more
- Volunteers
- 2,725 people
- Sponsor
- Boehringer Ingelheim
Acute Coronary Syndrome, Adverse Reaction to Antiplatelet Agent
Mojito Study (Mashed Or Just Integral Pill of TicagrelOr ? )
The aim of the Mashed Or Just Integral pill of TicagrelOr (MOJITO) study is to evaluate the superiority of Ticagrelor 180 mg LD mashed pill versus Ticagrelor 180 mg LD integral pill both orally administrated in decreasing…
- Trial name
- NCT01992523
- Testing
- Ticagrelor mashed pills, Ticagrelor integral pills
- Where
- 2 sites in Greece, Italy
- Volunteers
- 82 people
- Sponsor
- David Antoniucci
Acute Coronary Syndrome
Brilinta DaYu Study
A multicenter, single arm, open label, Phase IV study to evaluate safety and to describe the incidence of major cardiovascular events of ticagrelor in Chinese patients with acute coronary syndrome
- Trial name
- DaYu (NCT01870921)
- Testing
- Ticagrelor
- Where
- 39 sites in China
- Volunteers
- 2,004 people
- Sponsor
- AstraZeneca
Healthy
Study to Evaluate the Safety, Tolerability, PK, and PD of PB2452 in Healthy Volunteers
This is a Phase 1, first-in-human, randomized, double-blind, placebo-controlled, single ascending dose, sequential group study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of PB2452 with and…
- Trial name
- NCT03492385
- Testing
- PB2452 Infusion, Ticagrelor Oral Tablet - Pre-Treatment, Ticagrelor Oral Tablet - Pre-Treatment and Post-Treatment
- Where
- United States
- Volunteers
- 64 people, healthy volunteers welcome
- Sponsor
- SFJ Pharmaceuticals, Inc.
Diabetes Mellitus, Type 2, Coronary Artery Disease
Low Maintenance Dose Ticagrelor Versus Clopidogrel in Diabetes Patients Undergoing PCI
To date there is very little PD and pharmacokinetic (PK) data on the ticagrelor 60 mg bid dosing regimen. In particular, there is no prospective PK/PD study on this dosing regimen in patients with DM who are known to have…
- Trial name
- OPTIMUS-6 (NCT03437044)
- Testing
- Ticagrelor, Clopidogrel
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- University of Florida
Coronary Artery Disease, Diabetes Mellitus
Impact of Chronic Kidney Disease on the Effects of Ticagrelor in Patients With Diabetes and Coronary Artery Disease
Patients with diabetes mellitus (DM) are at increased risk of atherothrombotic events. Importantly, DM is a key risk factor for the development of chronic kidney disease (CKD), which further enhances atherothrombotic risk.
- Trial name
- NCT02539160
- Testing
- ticagrelor
- Where
- United States
- Volunteers
- 101 people
- Sponsor
- University of Florida
Acute Coronary Syndrome
Ad Hoc Percutaneous Coronary Intervention Study in Acute Coronary Syndrome Patients
The purpose of this study is to assess the pharmacodynamic effect of ticagrelor in ACS patients undergoing an Ad Hoc PCI
- Trial name
- NCT01603082
- Testing
- Ticagrelor, Clopidogrel
- Where
- 16 sites in United States
- Volunteers
- 343 people
- Sponsor
- AstraZeneca
Coronary Artery Disease
A Pharmacodynamic Study Comparing Prasugrel Versus Ticagrelor in Patients Undergoing PCI With CYP2C19 Loss-of-function:
Numerous studies have shown that pharmacodynamics (PD) response profiles vary among clopidogrel treated patients and that individuals with reduced response have an increased risk of recurrent ischemic events.
- Trial name
- NCT02065479
- Testing
- Prasugrel, Ticagrelor
- Where
- United States
- Volunteers
- 65 people
- Sponsor
- University of Florida
Peripheral Artery Disease
A Study Comparing Cardiovascular Effects of Ticagrelor and Clopidogrel in Patients With Peripheral Artery Disease
The purpose of this study is to compare the effects of ticagrelor and clopidogrel in patients with Peripheral Artery Disease.
- Trial name
- EUCLID (NCT01732822)
- Testing
- Ticagrelor, Clopidogrel
- Where
- 776 sites in United States, Argentina and 26 more
- Volunteers
- 13,885 people
- Sponsor
- AstraZeneca
Coronary Artery Disease
Pharmacodynamic Evaluation of Switching From Ticagrelor to Prasugrel in Subjects With Stable Coronary Artery Disease
This is a Phase 4, multicenter, open-label (blinded Pharmacodynamic PD results), randomized, 3-arm, parallel-design study of subjects with stable Coronary Artery Disease CAD.
- Trial name
- SWAP-2 (NCT01587651)
- Testing
- Prasugrel Loading Dose, Prasugrel Maintenance Dose, Ticagrelor Maintenance Dose
- Where
- 13 sites in United States, United Kingdom
- Volunteers
- 110 people
- Sponsor
- Daiichi Sankyo
Healthy
Phase 2B Study to Evaluate the Efficacy of Bentracimab (PB2452) in Reversal of Ticagrelor in Subjects Aged 50-80 Years Old
This phase 2B study is a multi-center, randomized, double-blind, placebo-controlled study. The study is designed to evaluate the efficacy of bentracimab (PB2452) in reversing the anti-platelet effects of ticagrelor as part of a…
- Trial name
- NCT04122170
- Testing
- Ticagrelor Oral Tablet - Pre-Treatment, Aspirin (ASA) Oral Tablet - Pre-Treatment, Bentracimab (PB2452) Infusion
- Where
- 15 sites in United States, Canada
- Volunteers
- 207 people, healthy volunteers welcome
- Sponsor
- SFJ Pharmaceuticals, Inc.
Coronary Artery Disease
Impact of Ticagrelor Re-load on Pharmacodynamic Profiles
Platelets are parts of your blood that stick together to help form a clot. The stickier your platelets are, the greater your chance of having a heart attack. A clot in the wrong place can lead to a heart attack or stroke.
- Trial name
- NCT01731041
- Testing
- Ticagrelor 180mg, Ticagrelor 90mg
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- University of Florida
Acute Coronary Syndrome
Study of LC23-1306 in Healthy Male Subjects
This will be a dose block-randomized, double-blind, active and placebo controlled, single and multiple dosing, dose-escalation study to evaluate tolerability, safety and pharmacokinetic/pharmacodynamic characteristics.
- Trial name
- NCT01526577
- Testing
- LC23-1306, Ticagrelor
- Where
- South Korea
- Volunteers
- 113 people, healthy volunteers welcome
- Sponsor
- LG Life Sciences
Acute Coronary Syndrome
A Study to Compare the Safety of Rivaroxaban Versus Acetylsalicylic Acid in Addition to Either Clopidogrel or Ticagrelor Therapy in Participants With Acute Coronary Syndrome
The purpose of this study is to estimate the risk of bleeding with rivaroxaban, compared with acetylsalicylic acid (ASA), in addition to a single antiplatelet/ platelet adenosine diphosphate P2Y12 receptor antagonist (P2Y12…
- Trial name
- GEMINI ACS 1 (NCT02293395)
- Testing
- Acetylsalicylic acid, Rivaroxaban, Clopidogrel
- Where
- 259 sites in United States, Argentina and 18 more
- Volunteers
- 3,037 people
- Sponsor
- Janssen Research & Development, LLC
PRU(Platelet Reactivity Unit), APT(Antiplatelet Therapy)
Platelet Reactivity (High On-Treatment Platelet Reactivity) as Guidance for APT (Antiplatelet Therapy) Adjustment After PCI (Percutaneous Coronary Intervention)
Since thrombus formation is a very complex procedure in vivo, platelet function testing methods in vitro might only reflect the degree of inhibition of platelet from a certain level, which do't reflect the functional status of…
- Conditions
- PRU(Platelet Reactivity Unit), APT(Antiplatelet Therapy), HOTPR(High on Treat Platelet Reactivity)
- Trial name
- NCT02101411
- Testing
- PRU(Platelet reactivity unit)
- Where
- Taiwan
- Volunteers
- 334 people
- Sponsor
- Taipei City Hospital
Coronary Artery Disease
Pharmacodynamic Effects of Prasugrel Compared With Ticagrelor in Patients With Coronary Artery Disease
Recently, two P2Y12 receptor inhibitors have been approved for clinical use: prasugrel and ticagrelor. Both prasugrel and ticagrelor have shown to be associated with more potent antiplatelet effects compared with clopidogrel and…
- Trial name
- NCT01852175
- Testing
- Prasugrel, Ticagrelor
- Where
- United States
- Volunteers
- 110 people
- Sponsor
- University of Florida
Cost Sharing, Acute Coronary Syndrome
Affordability and Real-world Antiplatelet Treatment Effectiveness After Myocardial Infarction Study
Current patterns of P2Y12 receptor inhibitor use provide an excellent opportunity to test the impact of copayment reduction on clinician choice of medication, patient adherence, and clinical outcomes.
- Trial name
- ARTEMIS (NCT02406677)
- Testing
- Study voucher card
- Where
- 272 sites in United States, Puerto Rico
- Volunteers
- 11,001 people
- Sponsor
- AstraZeneca
Healthy
Investigation of Drug-drug Interaction of Dabigatran and Ticagrelor
To investigate the pharmacokinetic and pharmacodynamic interaction of dabigatran and ticagrelor under steady state conditions; to investigate the effect of staggered administration of ticagrelor loading dose on dabigatran…
- Trial name
- NCT01734772
- Testing
- dabigatran etexilate, ticagrelor
- Where
- Germany
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Coronary Artery Disease, Healthy Participants
A Study to Evaluate BMS-986141 Added on to Aspirin or Ticagrelor or the Combination, on Thrombus Formation in a Thrombosis Chamber Model in Participants With Stable Coronary Artery Disease and Healthy Participants
The purpose of this study is to assess the effectiveness, safety and tolerability of BMS-986141 added on to aspirin or ticagrelor or the combination on thrombus formation in both healthy participants and participants with stable…
- Trial name
- NCT05093790
- Testing
- Ticagrelor, BMS-986141, Aspirin
- Where
- United Kingdom
- Volunteers
- 58 people, healthy volunteers welcome
- Sponsor
- Bristol-Myers Squibb